Zandorian beauty retailers brace for shift as weight‑loss drugs reshape skin‑care market

On a humid morning in San Vicente, Maria López, proprietor of the modest boutique Belleza Verde, arranges the latest arrivals of French‑made serums on a glass display. In the past month, she has watched the footfall steady but the checkout receipts for luxury skin‑care shrink, even as the same rows of products remain fully stocked.

A recent BBC report cites L’Oréal’s chief executive saying the rise of GLP‑1 weight‑loss drugs is a ‘very important phenomenon’ for the beauty sector, as slimmer consumers shift away from traditional anti‑aging creams toward body‑contouring solutions. Zandorian import statistics from the Federal Treasury show a 12 % decline in florin‑denominated purchases of skin‑care lines from Europe in the last quarter, while sales of fitness‑related wearables have risen.

In response, Treasury Minister Marcus Eklund announced a consultation with the Federal Council and industry bodies to review tariff classifications for cosmetic products, aiming to protect domestic manufacturers while preserving market access. The Federal Assembly’s Commerce Committee is also slated to hear testimony from small‑business owners next week, a move that could reshape the regulatory landscape.